4basebio PLC (88Q)

Overview

4basebio PLC is a pivotal entity in the biotechnology field, focusing on the research, development, manufacturing, and commercialization of synthetic DNA and RNA products alongside targeted non-viral vector solutions. With a presence that spans the United States, Europe, and other international locations, the company has established itself as a crucial player in the provision of critical components for gene therapies and vaccines. Originally known as 4basebio UK Societas, the company underwent a rebranding in July 2021, adopting the name 4basebio PLC. Since its inception in 2008, the company has set up its headquarters in Cambridge, United Kingdom, marking its commitment to innovation in the biotech sector.

Products and Services

• AVV and Lentivirus Manufacturing Services

  4basebio PLC offers comprehensive manufacturing services for Adeno-Associated Virus (AAV) and Lentivirus vectors. These services are crucial for the development of gene therapies and vaccines, catering to the needs of biotechnological and pharmaceutical companies. By leveraging cutting-edge technology and extensive expertise, 4basebio ensures the production of high-quality viral vectors necessary for delivering genetic material into cells, thereby playing a critical role in the advancement of gene therapy.

• Non-Viral Delivery Platform - Hermes

  The company provides access to Hermes, its proprietary non-viral delivery platform, designed to offer a safer and potentially more efficient alternative to viral vector systems in gene therapy. The platform underscores 4basebio's commitment to innovation in non-viral gene delivery technologies, opening new avenues for the development of gene therapies that are less dependent on viral vectors, reducing potential risks, and expanding the range of treatable conditions through gene therapy.